L Caley1, L Smith2, H White3, D G Peckham4. 1. School of Medicine, Clinical Sciences Building, St James's University Hospital, Leeds, LS9 7TF, United Kingdom. Electronic address: L.R.Caley@leeds.ac.uk. 2. Clinical and Population Science Department, School of Medicine, University of Leeds, Leeds, United Kingdom. 3. Nutrition and Dietetic Group, School of Clinical and Applied Science, Leeds Beckett University, Leeds, United Kingdom. 4. School of Medicine, Clinical Sciences Building, St James's University Hospital, Leeds, LS9 7TF, United Kingdom; Department of Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
Abstract
BACKGROUND: Rate of change in lung function is used as a measure of disease progression and a predictor of mortality in individuals with cystic fibrosis (CF). The aim of this study was to determine the national rate of decline in percent predicted Forced Expiratory Volume in 1 second (ppFEV1) in adults in the UK accounting for age, sex and pancreatic status. METHODS: Data on ppFEV1 for adults with CF, excluding those post lung transplantation, was extracted from the UK CF registry between 2015 and 2017. Multilevel modelling was conducted to calculate the annual rate of change in ppFEV1 accounting for age, sex and pancreatic status. RESULTS: Overall annual ppFEV1 decline was -1.52% (95% CI: -1.66 to -1.38%) and -0.55% (95% CI: -0.86 to -0.23%) in pancreatic insufficient (PI) and sufficient (PS) adults respectively. In PI individuals, females had a greater rate of decline in ppFEV1. There were differences between age groups. The fastest rate of decline was observed in the 18-28 years group, declining -1.76% (95% CI: -2.06 to -1.46) and -1.61% (95% CI: -1.91 to -1.31) per year in PI females and males respectively. The pattern between the sexes and age categories was more inconsistent in the PS group. CONCLUSIONS: The average annual rates of decline in lung function in adults with CF in the UK are similar to reports from other large international cohorts. Pancreatic status has a marked impact on average rate of decline. Younger adults, especially females, have a faster rate of decline and need close monitoring.
BACKGROUND: Rate of change in lung function is used as a measure of disease progression and a predictor of mortality in individuals with cystic fibrosis (CF). The aim of this study was to determine the national rate of decline in percent predicted Forced Expiratory Volume in 1 second (ppFEV1) in adults in the UK accounting for age, sex and pancreatic status. METHODS: Data on ppFEV1 for adults with CF, excluding those post lung transplantation, was extracted from the UK CF registry between 2015 and 2017. Multilevel modelling was conducted to calculate the annual rate of change in ppFEV1 accounting for age, sex and pancreatic status. RESULTS: Overall annual ppFEV1 decline was -1.52% (95% CI: -1.66 to -1.38%) and -0.55% (95% CI: -0.86 to -0.23%) in pancreatic insufficient (PI) and sufficient (PS) adults respectively. In PI individuals, females had a greater rate of decline in ppFEV1. There were differences between age groups. The fastest rate of decline was observed in the 18-28 years group, declining -1.76% (95% CI: -2.06 to -1.46) and -1.61% (95% CI: -1.91 to -1.31) per year in PI females and males respectively. The pattern between the sexes and age categories was more inconsistent in the PS group. CONCLUSIONS: The average annual rates of decline in lung function in adults with CF in the UK are similar to reports from other large international cohorts. Pancreatic status has a marked impact on average rate of decline. Younger adults, especially females, have a faster rate of decline and need close monitoring.
Authors: Ankitha Madde; William Okoniewski; Don B Sanders; Clement L Ren; Daniel J Weiner; Erick Forno Journal: J Cyst Fibros Date: 2021-12-28 Impact factor: 5.527
Authors: Danya Muilwijk; Eyleen de Poel; Peter van Mourik; Sylvia W F Suen; Annelotte M Vonk; Jesse E Brunsveld; Evelien Kruisselbrink; Hugo Oppelaar; Marne C Hagemeijer; Gitte Berkers; Karin M de Winter-de Groot; Sabine Heida-Michel; Stephan R Jans; Hannah van Panhuis; Menno M van der Eerden; Renske van der Meer; Jolt Roukema; Edward Dompeling; Els J M Weersink; Gerard H Koppelman; Robert Vries; Domenique D Zomer-van Ommen; Marinus J C Eijkemans; Cornelis K van der Ent; Jeffrey M Beekman Journal: Eur Respir J Date: 2022-08-18 Impact factor: 33.795
Authors: Renate Kos; Joël Israëls; Christine D L van Gogh; Josje Altenburg; Sandra Diepenhorst; Tamara Paff; Elles M J Boon; Dimitra Micha; Gerard Pals; Anne H Neerincx; Anke H Maitland-van der Zee; Eric G Haarman Journal: Am J Med Genet C Semin Med Genet Date: 2022-03-27 Impact factor: 3.359
Authors: J S Guimbellot; A Baines; A Paynter; S L Heltshe; J VanDalfsen; M Jain; S M Rowe; S D Sagel Journal: J Cyst Fibros Date: 2020-11-25 Impact factor: 5.482